BACKGROUND: Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands of lives in Africa. Nations such as Malawi, where Rotarix is currently under phase III investigation, may nevertheless face difficult economic choices in considering vaccine adoption. METHODS: The cost-effectiveness of implementing a Rotarix vaccine program in Malawi was estimated using published estimates of rotavirus burden, vaccine efficacy, and health care utilization and costs. RESULTS: With 49.5% vaccine efficacy, a Rotarix program could avert 2582 deaths annually. With GAVI Alliance cofinancing, adoption of Rotarix would be associated with a cost of $5.07 per disability-adjusted life-year averted. With market pricing, Rotarix would be associated with a base case cost of $74.73 per disability-adjusted life-year averted. Key variables influencing results were vaccine efficacy, under-2 rotavirus mortality, and program cost of administering each dose. CONCLUSIONS: Adopting Rotarix would likely be highly cost-effective for Malawi, particularly with GAVI support. This finding holds true across uncertainty ranges for key variables, including efficacy, for which data are becoming available.
BACKGROUND: Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands of lives in Africa. Nations such as Malawi, where Rotarix is currently under phase III investigation, may nevertheless face difficult economic choices in considering vaccine adoption. METHODS: The cost-effectiveness of implementing a Rotarix vaccine program in Malawi was estimated using published estimates of rotavirus burden, vaccine efficacy, and health care utilization and costs. RESULTS: With 49.5% vaccine efficacy, a Rotarix program could avert 2582 deaths annually. With GAVI Alliance cofinancing, adoption of Rotarix would be associated with a cost of $5.07 per disability-adjusted life-year averted. With market pricing, Rotarix would be associated with a base case cost of $74.73 per disability-adjusted life-year averted. Key variables influencing results were vaccine efficacy, under-2 rotavirus mortality, and program cost of administering each dose. CONCLUSIONS: Adopting Rotarix would likely be highly cost-effective for Malawi, particularly with GAVI support. This finding holds true across uncertainty ranges for key variables, including efficacy, for which data are becoming available.
Authors: Gustavo H Dayan; Lisa Cairns; Nalinee Sangrujee; Anne Mtonga; Van Nguyen; Peter Strebel Journal: Vaccine Date: 2004-01-02 Impact factor: 3.641
Authors: N A Cunliffe; J S Gondwe; C D Kirkwood; S M Graham; N M Nhlane; B D Thindwa; W Dove; R L Broadhead; M E Molyneux; C A Hart Journal: Lancet Date: 2001-08-18 Impact factor: 79.321
Authors: F R Velázquez; D O Matson; J J Calva; L Guerrero; A L Morrow; S Carter-Campbell; R I Glass; M K Estes; L K Pickering; G M Ruiz-Palacios Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: Umesh D Parashar; Erik G Hummelman; Joseph S Bresee; Mark A Miller; Roger I Glass Journal: Emerg Infect Dis Date: 2003-05 Impact factor: 6.883
Authors: Nicole G Campos; Jane J Kim; Philip E Castle; Jesse D Ortendahl; Meredith O'Shea; Mireia Diaz; Sue J Goldie Journal: Int J Cancer Date: 2011-08-24 Impact factor: 7.396
Authors: Nigel A Cunliffe; Desiree Witte; Bagrey M Ngwira; Stacy Todd; Nancy J Bostock; Ann M Turner; Philips Chimpeni; John C Victor; A Duncan Steele; Alain Bouckenooghe; Kathleen M Neuzil Journal: Vaccine Date: 2012-04-27 Impact factor: 3.641
Authors: Wilm Quentin; Fern Terris-Prestholt; John Changalucha; Selephina Soteli; W John Edmunds; Raymond Hutubessy; David A Ross; Saidi Kapiga; Richard Hayes; Deborah Watson-Jones Journal: BMC Med Date: 2012-11-13 Impact factor: 8.775